Last 48 quarters of trend data · Healthcare · Medical - Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -10.93 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 2.35 | 3.41 | 3.11 | 1.93 | 1.69 | 2.01 | 1.29 | 1.06 | 0.93 | 0.96 | 1.15 | 1.55 | 2.31 | 3.21 | 2.05 | 1.60 | 4.26 | 4.91 | 4.50 | 6.55 | 10.05 |
| — | +69.2% | +141.2% | +81.4% | +81.0% | +110.9% | +12.3% | -31.4% | -59.6% | -70.2% | -44.0% | -3.6% | -45.6% | -34.6% | -54.4% | -75.5% | -57.6% | -37.8% | -53.1% | +21.7% | +73.4% | |
| P/B Ratio | 8.39 | 17.07 | 11.89 | 9.95 | 14.34 | 12.29 | 4.57 | 4.21 | 3.84 | 3.11 | 2.30 | 3.37 | 3.30 | 4.74 | 2.75 | 2.14 | 3.68 | 4.37 | 4.51 | 8.16 | 8.70 |
| — | +38.9% | +159.9% | +136.2% | +273.7% | +295.1% | +98.7% | +24.9% | +16.2% | -34.4% | -16.3% | +57.4% | -10.2% | +8.3% | -39.0% | -73.7% | -57.7% | -28.7% | -18.1% | +111.2% | +247.3% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | 7.87 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | 167.21 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | 148.63 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 36.0% | 63.9% | 37.4% | -10.5% | 64.4% | 62.3% | 60.1% | 63.0% | 60.5% | 23.1% | 58.1% | 27.7% | 66.6% | 68.4% | 62.4% | 65.3% | 63.2% | 67.2% | 65.8% | 72.2% | 68.1% |
| — | +2.6% | -37.7% | -116.7% | +6.4% | +169.2% | +3.4% | +127.5% | -9.1% | -66.2% | -6.9% | -57.6% | +5.5% | +1.8% | -5.2% | -9.5% | -7.2% | +0.1% | -3.0% | +7.5% | +0.2% | |
| Operating Margin | -12.2% | -13.0% | -7.3% | 0.1% | -6.5% | -22.6% | -32.4% | -21.4% | -31.6% | -45.7% | -64.6% | -39.4% | -38.7% | -9.1% | -46.2% | -47.0% | -63.4% | -58.1% | -47.0% | -10.1% | -33.5% |
| — | +42.5% | +77.5% | +100.3% | +79.6% | +50.4% | +49.9% | +45.6% | +18.3% | -401.6% | -39.7% | +16.3% | +39.0% | +84.3% | +1.7% | -367.8% | -89.2% | -61.2% | +14.4% | +43.8% | +46.6% | |
| Net Margin | -21.2% | -23.4% | -16.9% | -6.8% | -15.4% | -33.2% | -44.0% | -32.5% | -40.9% | -54.0% | -74.0% | -65.5% | -38.7% | -7.3% | -28.7% | -48.0% | -63.2% | -52.7% | -47.6% | -11.9% | -35.7% |
| — | +29.7% | +61.6% | +79.2% | +62.4% | +38.4% | +40.5% | +50.3% | -5.9% | -636.7% | -157.8% | -36.6% | +38.9% | +86.1% | +39.7% | -302.9% | -77.2% | -46.3% | +16.1% | +10.6% | +33.4% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -76.9% | -26.8% | -15.1% | -12.4% | -29.3% | -41.7% | -33.2% | -36.3% | -36.0% | -37.1% | -32.0% | -31.8% | -13.2% | -2.7% | -9.4% | -15.1% | -13.0% | -11.3% | -11.4% | -3.7% | -7.5% |
| — | +35.7% | +54.6% | +65.7% | +18.6% | -12.7% | -3.9% | -14.2% | -173.5% | -1259.7% | -239.7% | -110.0% | -0.9% | +75.9% | +17.8% | -310.2% | -73.5% | -64.6% | -44.9% | -54.7% | -32.2% | |
| ROA | -17.0% | -5.2% | -3.2% | -2.1% | -3.4% | -6.4% | -6.6% | -7.4% | -7.5% | -9.6% | -10.1% | -13.9% | -7.6% | -1.7% | -6.4% | -11.3% | -10.0% | -8.9% | -9.0% | -2.9% | -6.1% |
| — | +18.1% | +51.1% | +71.6% | +54.0% | +33.7% | +34.3% | +46.8% | +1.8% | -477.7% | -57.5% | -22.6% | +24.4% | +81.2% | +28.9% | -285.1% | -63.4% | -54.1% | -33.7% | -43.7% | -26.3% | |
| ROIC | -22.1% | -6.1% | -3.1% | 0.0% | -3.3% | -10.8% | -11.5% | -10.5% | -12.7% | -19.5% | -22.8% | -18.2% | -11.9% | -3.0% | -14.5% | -15.7% | -15.7% | -17.7% | -18.6% | -5.3% | -12.5% |
| — | +43.6% | +72.8% | +100.4% | +73.7% | +44.6% | +49.6% | +42.1% | -6.7% | -552.8% | -56.6% | -15.7% | +24.5% | +83.1% | +21.9% | -194.9% | -26.0% | -30.2% | -14.7% | +23.0% | +16.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.65 | 3.57 | 3.02 | 2.65 | 6.45 | 5.24 | 3.66 | 2.70 | 3.47 | 2.59 | 1.89 | 1.43 | 0.43 | 0.39 | 0.26 | 0.02 | 0.02 | 0.02 | 0.00 | 0.01 | 0.01 |
| — | -31.8% | -17.5% | -1.9% | +85.9% | +102.1% | +93.7% | +89.1% | +709.8% | +560.9% | +618.8% | +6689.9% | +2122.0% | +2158.5% | +5904.4% | +273.0% | +166.8% | +104.1% | -52.8% | -46.7% | -54.7% | |
| Debt / EBITDA | — | — | — | 169.57 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.00 | 5.68 | 5.80 | 5.00 | 4.44 | 4.72 | 5.45 | 5.26 | 5.46 | 5.33 | 5.87 | 5.52 | 4.87 | 2.78 | 2.84 | 3.63 | 4.14 | 4.45 | 4.72 | 4.60 | 5.11 |
| — | +20.3% | +6.4% | -5.1% | -18.6% | -11.3% | -7.1% | -4.7% | +12.0% | +91.7% | +106.3% | +52.3% | +17.8% | -37.6% | -39.8% | -21.2% | -19.1% | -22.3% | -27.1% | -36.3% | -27.5% | |
| Quick Ratio | 4.26 | 4.53 | 4.79 | 4.26 | 3.61 | 3.95 | 4.64 | 4.56 | 4.52 | 4.45 | 4.94 | 4.74 | 3.78 | 2.19 | 2.25 | 2.63 | 3.06 | 3.60 | 4.12 | 4.09 | 4.60 |
| — | +14.8% | +3.2% | -6.5% | -20.1% | -11.3% | -6.0% | -3.9% | +19.6% | +103.0% | +119.2% | +80.3% | +23.3% | -39.1% | -45.3% | -35.6% | -33.4% | -31.3% | -31.6% | -39.7% | -29.1% | |
| Interest Coverage | -0.94 | -1.11 | -0.46 | 0.19 | -0.33 | -1.65 | -2.00 | -1.76 | -2.26 | -3.58 | -4.40 | -7.55 | -7.54 | -0.76 | -23.78 | -1970.33 | -5744.00 | -1783.67 | -736.25 | -1875.00 | -1386.00 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying APYX stock.
Apyx Medical Corporation's current P/E is -10.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Apyx Medical Corporation's current operating margin is -12.2%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Apyx Medical Corporation's business trajectory between earnings reports.